Bioxytran (OTCMKTS:BIXT) Issues Quarterly Earnings Results

Bioxytran (OTCMKTS:BIXT) announced its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Bioxytran Stock Up 16.7 %

OTCMKTS BIXT opened at $0.15 on Friday. The firm has a market capitalization of $12.96 million, a PE ratio of -14.70 and a beta of 0.98. The stock’s 50 day moving average is $0.11 and its 200 day moving average is $0.10. Bioxytran has a twelve month low of $0.06 and a twelve month high of $0.21.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.